Related Experiment Video
Updated: Jan 7, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Integrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation of Oncology Drugs
Maryam Sadat Mirlohi1, Tooba Yousefi2, Amir Reza Aref3,4
1Department of Mechanical Engineering, University of Victoria, Victoria, BC V8W 2Y2, Canada.
Abstract:
Traditional animal-based preclinical models, including xenografts and genetically engineered mice, have been used for assessing pharmacodynamics, toxicity, efficacy, and safety for decades. Despite their limited ability to mimic human tumor heterogeneity, immune interactions, and microenvironmental complexity, over 90% of oncology candidates that succeed in animal studies fail in clinical trials. The New Approach Methodologies (NAMs), which include patient-derived organoids, organ-on-chip platforms, and AI-driven computational models, provide human-relevant solutions that can improve predictive validity, mechanistic insight, and ethics. Through these technologies, it will be possible to replicate tumor biology specific to patients, to support co-clinical trial designs, and to facilitate biomarker discovery while reducing animal testing. Several recent regulatory reforms, including the Food and Drug Administration (FDA) Modernization Act 2.0 and the European Medicines Agency's NAM qualification framework, have established clear pathways for the integration of validated NAMs into preclinical drug evaluation. Critically evaluating the scientific rationale, comparative performance, and regulatory context of key NAM platforms in oncology, this review highlights opportunities for synergistic integration, technical refinement, and global harmonization in order to accelerate the development of clinically effective cancer therapeutics based on preclinical findings.
Insights
New Approach Methodologies (NAMs) offer human-relevant alternatives to traditional animal models for cancer drug development. These advanced methods improve predictive accuracy and ethical considerations, accelerating the creation of effective cancer therapies.
Area of Science:
- Oncology
- Preclinical Research
- Drug Development
Background:
- Traditional animal models (xenografts, genetically engineered mice) have limitations in replicating human tumor complexity, leading to high failure rates (over 90%) of oncology candidates in clinical trials.
- Existing preclinical models struggle to accurately mimic human tumor heterogeneity, immune interactions, and microenvironmental factors, impacting drug efficacy predictions.
Purpose of the Study:
- To critically evaluate New Approach Methodologies (NAMs) as human-relevant alternatives in preclinical oncology drug development.
- To highlight the potential of NAMs, including organoids, organ-on-chip, and AI models, to improve predictive validity, mechanistic insight, and ethical standards in cancer research.
- To review regulatory advancements supporting NAM integration and identify opportunities for refinement and harmonization.
Main Methods:
- Review of scientific literature on traditional animal models and emerging NAMs in oncology.
- Analysis of the capabilities of patient-derived organoids, organ-on-chip platforms, and AI-driven computational models.
- Examination of regulatory frameworks, such as the FDA Modernization Act 2.0 and EMA's NAM qualification framework.
Main Results:
- NAMs offer improved replication of patient-specific tumor biology, enabling better co-clinical trial designs and biomarker discovery.
- Regulatory reforms are creating clear pathways for the validation and integration of NAMs into preclinical drug evaluation.
- Synergistic integration, technical refinement, and global harmonization of NAMs can accelerate the development of effective cancer therapeutics.
Conclusions:
- New Approach Methodologies represent a significant advancement over traditional animal models for preclinical cancer research.
- The adoption of validated NAMs, supported by regulatory initiatives, is crucial for enhancing the predictive power and ethical considerations in oncology drug development.
- Further refinement and harmonization of NAMs are needed to fully realize their potential in accelerating the delivery of clinically effective cancer treatments.
Related Concept Videos
01:28Preclinical Development: Overview
01:11Clinical Trials: Overview
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:26Drug Discovery: Overview
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:10In Vitro Drug Release Testing: Overview, Development and Validation